Skip to main content
. Author manuscript; available in PMC: 2022 Sep 14.
Published in final edited form as: Biomed Pharmacother. 2022 Jul 20;153:113440. doi: 10.1016/j.biopha.2022.113440

Fig. 5.

Fig. 5.

Effect of the treatment with MON or its analog 1 on PARP, STAT3, p-STAT3, p-AKT, p-GSK-3β, and ɣH2AX expression. U-118MG organoids were treated with 0.1% DMSO (control), or 3 μM MON, 1.5 μM compound 1 for 24 or 48 h as indicated, and extracts were prepared as described in the Materials and methods and subjected to immunoblotting with anti-sera indicated. GAPDH was used as a loading control. A. Representative immunoblots; B-G. Bar diagrams representing the fold changes of proteins normalized to GAPDH. Immunoblots were quantified with ImageJ software by measuring the band densitometry. Data represent mean ± SD (n = 3), *p ≤ 0.05, **p ≤ 0.01, *** p ≤ 0.001, ****p ≤ 0.0001.